Based on the findings presented in this manuscript, we aim to include sarcopenia and frailty in the decision-making processes regarding bladder cancer patients, using low ALT values as a marker for sarcopenia, frailty, and shortened survival. This evidence concerns the gene GPT and urinary bladder cancer.